Results 151 to 160 of about 12,380 (194)
Stent Thrombosis: A Narrative Review From Pathophysiology to Therapy. [PDF]
Clin CardiolCecchi E +8 more
europepmc +1 more source
Prevalence and predictors of dyspnea in acute coronary syndrome patients receiving ticagrelor: A prospective cohort study in Iran. [PDF]
Medicine (Baltimore)Taherkhani M +4 more
europepmc +1 more source
Comprehensive Review of Antiplatelet Therapy in Secondary Prevention of Myocardial Infarction: Mechanisms, Clinical Evidence, and Future Directions. [PDF]
Cardiovasc TherKyaw MT, Moe A.
europepmc +1 more source
Idiopathic esophageal submucosal hematoma after flow diverter stent placement for an unruptured intracranial aneurysm: illustrative case. [PDF]
J Neurosurg Case LessonsShimura S +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Hämostaseologie, 2012
SummaryThe antithrombotic therapy in patients with atherosclerotic vascular disease is subject of several new therapeutic approaches. Simultaneous treatment with aspirin and a thienopyridin (clopidogrel) represents the standard of care for patients with acute coronary syndrome and following coronary stenting recommended by many guidelines. Without true
Antonio, Tello-Montoliu +2 more
+10 more sources
SummaryThe antithrombotic therapy in patients with atherosclerotic vascular disease is subject of several new therapeutic approaches. Simultaneous treatment with aspirin and a thienopyridin (clopidogrel) represents the standard of care for patients with acute coronary syndrome and following coronary stenting recommended by many guidelines. Without true
Antonio, Tello-Montoliu +2 more
+10 more sources
Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction [PDF]
Circulation, 2020 BACKGROUND Standard administration of newer oral P2Y$_{12}$ inhibitors, including prasugrel or ticagrelor, provides suboptimal early inhibition of platelet aggregation (IPA) in patients with ST-segment-elevation myocardial infarction undergoing primary ...
Giuseppe Gargiulo +2 more
exaly +2 more sources
Expert Opinion on Investigational Drugs, 2006
Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyridine (a P2Y(12) receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes.
Udaya S, Tantry +2 more
openaire +4 more sources
Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyridine (a P2Y(12) receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes.
Udaya S, Tantry +2 more
openaire +4 more sources
International Journal of Cardiology, 2013
Recently, clopidogrel has beenproved to be reduced or complete lack of clinical benefit in nonsmokers in post-hoc analysis of several largescale randomized controlled trials (RCTs). These observations raise concerns about the costs and potential risks incurred by treating nonsmokers with clopidogrel [1].
Yicong, Ye +3 more
openaire +2 more sources
Recently, clopidogrel has beenproved to be reduced or complete lack of clinical benefit in nonsmokers in post-hoc analysis of several largescale randomized controlled trials (RCTs). These observations raise concerns about the costs and potential risks incurred by treating nonsmokers with clopidogrel [1].
Yicong, Ye +3 more
openaire +2 more sources